Identification

Generic Name
Satraplatin
DrugBank Accession Number
DB04996
Background

Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 500.283
Monoisotopic: 499.060437065
Chemical Formula
C10H22Cl2N2O4Pt
Synonyms
  • Satraplatin
External IDs
  • BMS-182751
  • BMY-45594
  • JM-216

Pharmacology

Indication

Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

This drug binds to the DNA of cancer cells, inhibiting cell division.

TargetActionsOrganism
UDNANot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CabazitaxelThe risk or severity of adverse effects can be increased when Satraplatin is combined with Cabazitaxel.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Satraplatin.
DocetaxelThe risk or severity of adverse effects can be increased when Satraplatin is combined with Docetaxel.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Satraplatin.
FosphenytoinSatraplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Satraplatin.
PaclitaxelThe risk or severity of adverse effects can be increased when Satraplatin is combined with Paclitaxel.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Satraplatin.
PhenytoinSatraplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
TopotecanThe risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
L01XA04 — Satraplatin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Cyclohexylamines
Direct Parent
Cyclohexylamines
Alternative Parents
Acetate salts / Organic transition metal salts / Organic metal halides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Organic chloride salts / Monoalkylamines / Hydrocarbon derivatives
show 1 more
Substituents
Acetate salt / Aliphatic homomonocyclic compound / Amine / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Cyclohexylamine / Hydrocarbon derivative / Monocarboxylic acid or derivatives
show 10 more
Molecular Framework
Not Available
External Descriptors
platinum coordination entity (CHEBI:85609)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
8D7B37T28G
CAS number
129580-63-8
InChI Key
CKNPWBAXEKSCRG-UHFFFAOYSA-J
InChI
InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
IUPAC Name
platinum(4+) cyclohexanamine diacetate amine dichloride
SMILES
N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1

References

General References
Not Available
PubChem Compound
123974
PubChem Substance
175426927
ChemSpider
110493
RxNav
1733681
ChEBI
85609
ChEMBL
CHEMBL3833367
Wikipedia
Satraplatin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentHormone Refractory Prostate Cancer / Prostate Cancer1
3TerminatedTreatmentProstate Cancer1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMetastatic Breast Cancer1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPolymorphism, Genetic / Prostate Cancer1
2CompletedTreatmentProstate Cancer1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentNeoplasms, Brain / Solid Tumors / Tumors Metastatic to Brain1
1RecruitingTreatmentProstate Cancer Patients1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility0.4 mg/ml at pH 1-7.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.5 mg/mLALOGPS
logP1.51ALOGPS
logP1.17ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)10.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity30.93 m3·mol-1ChemAxon
Polarizability12.44 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.6502
Blood Brain Barrier+0.7841
Caco-2 permeable-0.6468
P-glycoprotein substrateNon-substrate0.6858
P-glycoprotein inhibitor INon-inhibitor0.9881
P-glycoprotein inhibitor IINon-inhibitor0.9863
Renal organic cation transporterNon-inhibitor0.9154
CYP450 2C9 substrateNon-substrate0.8261
CYP450 2D6 substrateNon-substrate0.8462
CYP450 3A4 substrateNon-substrate0.6351
CYP450 1A2 substrateNon-inhibitor0.8764
CYP450 2C9 inhibitorNon-inhibitor0.905
CYP450 2D6 inhibitorNon-inhibitor0.9427
CYP450 2C19 inhibitorNon-inhibitor0.866
CYP450 3A4 inhibitorNon-inhibitor0.8794
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9813
Ames testNon AMES toxic0.6304
CarcinogenicityNon-carcinogens0.811
BiodegradationReady biodegradable0.6692
Rat acute toxicity2.4085 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9732
hERG inhibition (predictor II)Non-inhibitor0.9639
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Nucleotide
Organism
Humans
Pharmacological action
Unknown
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51